Genome-wide localization of small molecules

Nature Biotechnology

Volumn 32, Issue 1, 2014, Pages 92-96

  Anders, Lars ^a   Guenther, Matthew G ^a   Qi, Jun ^b   Fan, Zi Peng ^a,c   Marineau, Jason J ^b   Rahl, Peter B ^a   Lovén, Jakob ^a   Sigova, Alla A ^a   Smith, William B ^b   Lee, Tong Ihn ^a   Bradner, James E ^b,d   Young, Richard A ^a,c  

^a WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLULAR FUNCTION; CHEMICAL MOLECULES; CHEMICAL PERTURBATIONS; DIRECT INTERACTIONS; MASSIVELY PARALLELS; SMALL MOLECULES; TARGET PROTEINS; THERAPEUTIC DRUGS;

DNA SEQUENCES; LIGANDS; MOLECULES; PROTEINS;

GENES;

AT 7519; BRD2 PROTEIN; BRD3 PROTEIN; BRD4 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYL SULFOXIDE; DNA; GENOMIC DNA; HISTONE H3; JQ 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING PROTEIN; PROTEIN; PROTEIN INHIBITOR; PSORALEN; RNA POLYMERASE II; STREPTAVIDIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; BIOTINYLATION; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA SEQUENCE; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; GENOME ANALYSIS; GENOME WIDE OCCUPANCY ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN GENOME; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN INTERACTION; TUMOR GROWTH;

BINDING SITES; CHROMATIN; DNA; GENOME, HUMAN; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIGANDS; PROTEIN BINDING; PROTEINS; TRANSCRIPTION FACTORS;

EID: 84892164371     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2776     Document Type: Article

References (43)

1. Bell, O., Tiwari, V.K., Thoma, N.H. & Schubeler, D. Determinants and dynamics of genome accessibility. Nat. Rev. Genet. 12, 554-564 (2011).
2. Gilbert, D.M. Evaluating genome-scale approaches to eukaryotic DNA replication. Nat. Rev. Genet. 11, 673-684 (2010).
3. Hawkins, R.D., Hon, G.C. & Ren, B. Next-generation genomics: an integrative approach. Nat. Rev. Genet. 11, 476-486 (2010).
4. MacQuarrie, K.L., Fong, A.P., Morse, R.H. & Tapscott, S.J. Genome-wide transcription factor binding: beyond direct target regulation. Trends Genet. 27, 141-148 (2011).
5. Neph, S. et al. Circuitry and dynamics of human transcription factor regulatory networks. Cell 150, 1274-1286 (2012).
6. Zhou, V.W., Goren, A. & Bernstein, B.E. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 12, 7-18 (2011).
7. Ng, H.H. & Surani, M.A. The transcriptional and signalling networks of pluripotency. Nat. Cell Biol. 13, 490-496 (2011).
8. Northrup, D.L. & Zhao, K. Application of ChIP-Seq and related techniques to the study of immune function. Immunity 34, 830-842 (2011).
9. Orkin, S.H. & Hochedlinger, K. Chromatin connections to pluripotency and cellular reprogramming. Cell 145, 835-850 (2011).
10. Young, R.A. Control of the embryonic stem cell state. Cell 144, 940-954 (2011).
11. Arrowsmith, C.H., Bountra, C., Fish, P.V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384-400 (2012).
12. Copeland, R.A., Solomon, M.E. & Richon, V.M. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8, 724-732 (2009).
13. Dawson, M.A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
14. Deshpande, A.J., Bradner, J. & Armstrong, S.A. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol. 33, 563-570 (2012).
15. Sandoval, J. & Esteller, M. Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22, 50-55 (2012).
16. You, J.S. & Jones, P.A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9-20 (2012).
17. Raida, M. Drug target deconvolution by chemical proteomics. Curr. Opin. Chem. Biol. 15, 570-575 (2011).
18. Bantscheff, M. et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat. Biotechnol. 29, 255-265 (2011).
19. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010).
20. Taunton, J., Hassig, C.A. & Schreiber, S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411 (1996).
21. Tung, S.Y., Hong, J.Y., Walz, T., Moazed, D. & Liou, G.G. Chromatin affinity-precipitation using a small metabolic molecule: its application to analysis of O-acetyl-ADP-ribose. Cell. Mol. Life Sci. 69, 641-650 (2012).
22. Chung, C.W. et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54, 3827-3838 (2011).
23. Delmore, J.E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
24. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
25. Loven, J. et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334 (2013).
26. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010).
27. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
28. Santo, L. et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 29, 2325-2336 (2010).
29. Zhou, Q., Li, T. & Price, D.H. RNA polymerase II elongation control. Annu. Rev. Biochem. 81, 119-143 (2012).
30. Squires, M.S. et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol. Cancer Ther. 9, 920-928 (2010).
31. Kouzine, F. et al. Transcription-dependent dynamic supercoiling is a short-range genomic force. Nat. Struct. Mol. Biol. 20, 396-403 (2013).
32. Naughton, C. et al. Transcription forms and remodels supercoiling domains unfolding large-scale chromatin structures. Nat. Struct. Mol. Biol. 20, 387-395 (2013).
33. Marson, A. et al. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell 134, 521-533 (2008).
34. Lee, T.I., Johnstone, S.E. & Young, R.A. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat. Protoc. 1, 729-748 (2006).
35. Langmead, B., Trapnell, C., Pop, M. & Salzberg, S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
36. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, R137 (2008).
37. Guenther, M.G., Levine, S.S., Boyer, L.A., Jaenisch, R. & Young, R.A. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 130, 77-88 (2007).
38. Rada-Iglesias, A. et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 470, 279-283 (2011).
39. Creyghton, M.P. et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. USA 107, 21931-21936 (2010).
40. Kagey, M.H. et al. Mediator and cohesin connect gene expression and chromatin architecture. Nature 467, 430-435 (2010).
41. Rahl, P.B. et al. c-Myc regulates transcriptional pause release. Cell 141, 432-445 (2010).
42. Robinson, M.D., McCarthy, D.J. & Smyth, G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
43. Ross-Innes, C.S. et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481, 389-393 (2012).